Introduction {#s1}
============

Major abdominal surgery such as liver resection results in an acute systemic inflammatory response characterized by hemodynamic and metabolic changes that produce and release various chemical mediators, including stress hormones, free radicals, and cytokines ([@B9]; [@B22]). During liver resection, in order to reduce intraoperative blood loss, blockage to the inflow blood of the liver is needed (Pringle maneuver). The downside of this technique is the ischemia-reperfusion (IR) damage to liver cells ([@B37]). Inflammatory cytokines play a significant role in this process. Increased levels of inflammatory cytokines are connected with high postoperative mortality and morbidity ([@B2]). Consequently, more attention has evolved to regulating inflammatory responses that probably harmful to the surgery. Many protective measures have been applied to reduce hepatic IR injury, including intermittent or selective Pringle maneuver ([@B10]; [@B20]) and multiple pharmacological interventions such as erythropoietin, vitamin E, branched chain amino acids, prostaglandin E ([@B4]; [@B19]; [@B16]; [@B18]).

The properties of anti-inflammatory and immune modulating allow steroid to be widely used in a variety of diseases associated with inflammatory response ([@B3]; [@B33]). Some previous studies have showed that preoperative use of steroid may reduce pro-inflammatory cytokines, alleviate liver IR injury, maintain a stable coagulation function ([@B29]; [@B32]). However, steroid is a double-edged sword also with lots of drawbacks, which may lead to delayed wound healing, hyperglycemia, postoperative infection, impaired liver regeneration, and the reactivation of hepatitis virus ([@B14]; [@B28]). The potential side effects of preoperative steroid use are of great concern in liver surgery. Considering the advantages and disadvantages, the use of steroid before liver resection is still controversial owing to absence of standard treatment guideline. Although some meta-analyses have discussed this topic ([@B23]; [@B31]), the authors ignored the high heterogeneity in the pooled results. Besides, the authors only analyzed the overall complications and they did not analyze the specific complications which were the significant parameters to evaluate the safety of preoperative steroid use. It is necessary to perform an updated and comprehensive meta-analysis by including the latest studies. Therefore, we performed this meta-analysis to evaluate the benefit and safety of preoperative administration of steroid in patients undergoing liver resection and provide a reference for clinical practice.

Materials And Methods {#s2}
=====================

Literature Search Strategy {#s2_1}
--------------------------

This systematic review and meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement ([@B24]). A systematic literature search was conducted independently by two authors (LY and ZZ) in the PubMed, Embase, and Cochrane Library Central databases through 4 May 2019. The search strategies were based on combinations of the following keywords: "hepatectomy" OR "liver resection" OR "hepatic resection" OR "liver surgery" OR "surgery of the liver" AND "steroids" OR "cortisone" OR "corticosteroids" OR "glucocorticoid" OR "glucocorticosteroids" OR "methylprednis" OR "methylprednisolone" OR "predniso" OR "prednisone" OR "dexamethasone" OR "hydrocortisone" In addition, a manual search of all references of retrieved articles was performed. The literature search was restricted to human studies and articles published in English.

Inclusion and Exclusion Criteria {#s2_2}
--------------------------------

Only randomized controlled trials (RCTs) comparing preoperative use of steroid in patients undergoing liver resection with no use of steroid were included in this review. Exclusion criteria were: (1) retrospective studies, case-control studies and cohort studies, (2) liver transplantation studies, and (3) studies that did not directly investigate IR injury.

Data Extraction {#s2_3}
---------------

The following data were extracted independently by the same two authors, and disagreements were resolved by a third author (WW). Extracted data were: (1) study characteristics: first author, country, study design, publication year, and indications for liver resection; (2) patient characteristics: age, sex, number of patients in steroid group and control group, number of patients in each group divided according to Child-Pugh classification, and number of patients in each group divided based on underlying liver disease; (3) intraoperative data: operative time, hepatic ischemia time, intraoperative blood loss, method of vascular control, liver resection technique, number of major resection in each group; (4) postoperative data: total bilirubin (TB), C-reactive protein (CRP), interleukin (IL) 6, IL-10, alanine aminotransferase (ALT), aspartate aminotransferase (AST), postoperative hospital stay, and postoperative complications (overall complications, infection complications, wound complications, liver failure, bile leakage, and pleural effusion). Whenever relevant data were required, the corresponding authors were contacted *via* email. If contact was failed, data were measured from enlarged figures.

Statistical Analysis {#s2_4}
--------------------

All statistical analyses were performed using Review Manager (Version 5.3, Cochrane Collaboration, Oxford, England). The odds ratio (OR) and the mean difference (MD) with 95% confidence interval (CI) were used for dichotomous data and continuous data, respectively. Statistical analysis was performed with data mean and standard deviation for continuous data. If included studies provided only medians and data ranges, the means ± standard deviation were calculated using the methods described by [@B15]. Statistical heterogeneity was assessed by I^2^ value, an I^2^ value greater than 50% was regarded as significant heterogeneity ([@B12]). A random-effects model was selected in the case of significant heterogeneity. A *P* value \< 0.05 was considered to be statistically significant. The results were illustrated by forest plots. The quality of included studies was evaluated using Cochrane Collaboration's Risk of Bias Tool ([@B13]). Subgroup analyses were performed to seek potential heterogeneity source and identify subsets of patients who tended to benefit from steroid according to region (Japan, Italy, or Germany), method of vascular control (no Pringle maneuver, continuous or intermittent Pringle maneuver), sample size (\>40 or \<40), and drug regimen (dosage of 30 mg/kg or dosage of 500 mg). Sensitivity analyses were also performed by omitting the included studies in turn to analyze the stability of the pooled results.

Results {#s3}
=======

Study Selection and Characteristics {#s3_1}
-----------------------------------

The search strategy identified 3,215 articles, of which 236 were duplicates, 2,952 were not relevant to the subject and 20 did not fulfill the inclusion criteria. Total seven articles considered for inclusion ([@B39]; [@B26]; [@B1]; [@B30]; [@B34]; [@B11]; [@B8]). However, two studies ([@B1]; [@B30]) came from the same institution, including a part of overlapping patients, more detailed study was included ([@B1]). Finally, six studies meet the inclusion criteria was included in this meta-analysis ([@B39]; [@B26]; [@B1]; [@B34]; [@B11]; [@B8]). Study selection process is shown in [**Figure 1**](#f1){ref-type="fig"} following PRISMA guidelines ([@B24]). The publication time of these studies ranged from 2001 to 2016. Of the six included studies, three came from Italy, two from Japan, and one from Germany. A total 411 patients were included in this meta-analysis, of whom 206 were in the steroid group and 205 in the control group. Main characteristics of the included studies are summarized in [**Table 1**](#T1){ref-type="table"}. Characteristics of liver resection in the included studies are shown in [**Table 2**](#T2){ref-type="table"}.

![Flow diagram of the study retrieval and selection process.](fphar-10-01442-g001){#f1}

###### 

Main characteristics of the included studies.

  Author               Year   Country   Study design   No. of patients   Age (year)   Gender, M/F        Child-Pugh classification (A/B/C)   Steroid protocol   Outcome measure                                                                                                                    
  -------------------- ------ --------- -------------- ----------------- ------------ ------------------ ----------------------------------- ------------------ ----------------- -------- -------- ---------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------
  Aldrighetti et al.   2006   Italy     RCT            36                37           61.8 (21--78)^a^   63 (31--85)^a^                      22/14              23/14             36/0/0   37/0/0   MP 500 mg before anesthesia                                                                    ALT, AST, TB, INR, IL-6, complications, hospital stay
  Donadon et al.       2016   Italy     RCT            16                16           65 (27--80)^a^     63 (22--77)^a^                      10/6               9/7               NR       NR       MP 500 mg 1h before liver resection                                                            ALT, TB, complications, hospital stay
  Hayashi et al.       2011   Japan     RCT            102               98           69 (39--81)^a^     70 (35--72)^a^                      NR                 NR                99/3/0   94/4/0   HC 500 mg before hepatic pedicle clamping, 300 mg on POD 1, 200 mg on POD 2, 100 mg on POD 3   ALT, AST, TB, INR, CRP, IL-6, IL-10, complications, hospital stay
  Muratore et al.      2003   Italy     RCT            25                28           65.4 ± 10.8^b^     64.1 ± 11.7^b^                      17/8               11/17             NR       NR       MP 30 mg/kg 0.5 h before liver resection                                                       ALT, AST, TB, PT, IL-6, complications, hospital stay
  Schmidt et al.       2007   Germany   RCT            10                10           57^c^              65^c^                               3/7                4/6               NR       NR       MP 30 mg/kg 1.5 h before surgery                                                               ALT, AST, TB, INR, IL-6, IL-8, IL-10, TNF-α, CRP, complications, hospital stay
  Yamashita et al.     2001   Japan     RCT            17                16           60.3 ± 1.8^b^      56.8 ± 3.9^b^                       13/4               11/5              NR       NR       MP 500 mg 2 h before surgery                                                                   ALT, AST, TB, PT, IL-6, IL-10, CRP, complications, hospital stay

^a^Data expressed as median (range); ^b^data are expressed as mean ± SD; ^c^data are expressed as mean.

RCT, randomized controlled trial; MP, methylprednisolone; HC, hydrocortisone; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; CRP, C-reactive protein; IL, interleukin; TNF, tumor necrosis factor; PT, prothrombin time; NR, not reported.

###### 

Characteristics of liver resection of the included studies.

  Author               Year   Major resection   Vascular control   Resection technique             Indication of surgery (HCC/MLT/CCC/LDLT/GC/others)   Operative time (min)   Ischemia time (min) Steroid Control   Blood loss (mL)      Underlying liver disease (normal/cirrhosis/steatosis)                                                                                             
  -------------------- ------ ----------------- ------------------ ------------------------------- ---------------------------------------------------- ---------------------- ------------------------------------- -------------------- ------------------------------------------------------- ------------------ ------------------- -------------------- ------------------- --------- ---------
  Aldrighetti et al.   2006   26                27                 Intermittent Pringle maneuver   Ultrasonic dissector and ultrasonic scalpel          14/14/4/0/0/4          12/16/4/0/1/4                         408 (240--460)^a^    440 (220--480)^a^                                       52.4 (20--89)^a^   43 (20--78)^a^      621 (350--720)^a^    662 (300--800)^a^   18/14/4   21/12/4
  Donadon et al.       2016   7                 5                  Intermittent Pringle maneuver   Crush clamping                                       6/6/4/0/0/0            2/12/0/0/0/2                          383.5(235--546)^a^   351 (226--640)^a^                                       83 (46--162)^a^    80.5 (35--168)^a^   275 (100--1000)^a^   200 (0--700)^a^     NR        NR
  Hayashi et al.       2011   11                15                 Intermittent Pringle maneuver   NR                                                   63/32/6/0/0/1          66/23/5/0/0/4                         330 (165--834)^a^    316 (136--697)^a^                                       72 (0--247)^a^     60 (0--203)^a^      324 (5--1577)^a^     257 (10--1972)^a^   NR        NR
  Muratore et al.      2003   13                15                 Continuous Pringle maneuver     Ultrasonic dissector                                 NR                     NR                                    NR                   NR                                                      41.4 ± 15.9^b^     37.3 ± 17.8^b^      322.8 ± 261.4^b^     294.6 ± 271.9^b^    8/10/7    15/4/9
  Schmidt et al.       2007   6                 5                  No use                          Ultrasound dissector                                 2/4/0/0/0/4            1/4/2/0/0/3                           222^c^               252^c^                                                  NR                 NR                  340^c^               780^c^              NR        NR
  Yamashita et al.     2001   5                 6                  Continuous Pringle maneuver     NR                                                   13/0/0/4/0/0           8/3/1/4/0/0                           338 ± 87^b^          352 ± 56^b^                                             NR                 NR                  892 ± 437^b^         822 ± 220^b^        NR        NR

^a^Data expressed as median (range); ^b^data are expressed as mean ± SD; ^c^data are expressed as mean.

HCC, hepatocellular carcinoma; MLT, metastatic liver tumor; CCC, cholangiocellular carcinoma; LDLT, living donor liver transplantation; GC, gallbladder carcinoma; NR, not reported.

Postoperative Complications {#s3_2}
---------------------------

Postoperative complications reported in the included studies are summarized in [**Table 3**](#T3){ref-type="table"}. There was no significant difference in the incidence of overall complications between the steroid group and the control group (OR, 0.57; 95% CI, 0.27--1.17; *P* = 0.13) ([**Figure 2A**](#f2){ref-type="fig"}). In terms of specific complications, no significant difference was detected between the two groups in infection complications (OR, 0.95; 95% CI, 0.13--6.95; *P* = 0.96) ([**Figure 2B**](#f2){ref-type="fig"}), wound complications (OR, 0.65; 95% CI, 0.32--1.33; *P* = 0.24) ([**Figure 2C**](#f2){ref-type="fig"}), liver failure (OR, 0.41; 95% CI, 0.10--1.64; *P* = 0.21) ([**Figure 2D**](#f2){ref-type="fig"}), bile leakage (OR, 0.57; 95% CI, 0.17--1.89; *P* = 0.36) ([**Figure 2E**](#f2){ref-type="fig"}), and pleural effusion (OR, 1.24; 95% CI, 0.55--2.78; *P* = 0.60) ([**Figure 2F**](#f2){ref-type="fig"}). There were no postoperative deaths in all studies.

###### 

Postoperative complications reported in the included studies.

  Complications (n)         [@B1]   [@B8]   [@B11]   [@B26]   [@B34]   [@B39]                               
  ------------------------- ------- ------- -------- -------- -------- -------- ---- ---- ----- ----- ----- -----
  Infection complications   2       8       NR       NR       16       5        NR   NR   ---   ---   1     1
  Liver failure             2       4       NR       NR       1        3        NR   NR   ---   ---   ---   ---
  Bile leakage              0       1       NR       NR       3        5        NR   NR   1     1     ---   ---
  Ascites                   ---     ---     NR       NR       ---      ---      NR   NR   ---   ---   1     0
  Wound complications       0       2       NR       NR       13       15       NR   NR   0     1     0     1
  Hemorrhage                0       1       NR       NR       ---      ---      NR   NR   ---   ---   ---   ---
  Cardiovascular            0       3       NR       NR       ---      ---      NR   NR   ---   ---   ---   ---
  Pleural effusion          1       1       NR       NR       14       11       NR   NR   ---   ---   ---   ---
  Bile duct stenosis        ---     ---     NR       NR       ---      ---      NR   NR   1     1     ---   ---
  Reoperation               ---     ---     NR       NR       1        3        NR   NR   ---   ---   ---   ---
  Atelectasis               ---     ---     NR       NR       5        8        NR   NR   ---   ---   ---   ---
  Side effect of steroids   ---     ---     NR       NR       ---      ---      NR   NR   ---   ---   ---   ---
  Death                     ---     ---     NR       NR       ---      ---      NR   NR   ---   ---   ---   ---
  Total events              5       20      3        2        53       50       7    12   2     3     2     2
  Overall complications\*   5       20      3        2        41       42       7    12   2     3     2     2

NR, not reported; SG, steroid group; CG, control group.

\*Number of patients.

![The pooled results of comparison between the steroid group and the control group for postoperative complications illustrated by forest plots. The results were overall complications **(A)**, infection complications **(B)**, wound complications **(C)**, liver failure **(D)**, bile leakage **(E)**, pleural effusion **(F)**.](fphar-10-01442-g002){#f2}

Postoperative Liver Function {#s3_3}
----------------------------

The level of serum TB on postoperative day 1 (POD 1) was significantly decreased associated with the intervention of steroids (MD, −0.54; 95% CI, −0.94 to −0.15; *P* = 0.007) ([**Figure 3A**](#f3){ref-type="fig"}). There was no significant difference in the level of ALT (MD, −69.39; 95% CI, −226.52 to 87.75; *P* = 0.39) ([**Figure 3B**](#f3){ref-type="fig"}) and AST (MD, −93.44; 95% CI, −275.68 to 88.80; *P* = 0.31) ([**Figure 3C**](#f3){ref-type="fig"}) on POD 1 between the steroid group and the control group.

![The pooled results of comparison between the steroid group and the control group for postoperative liver function illustrated by forest plots. The results were TB on POD 1 **(A)**, ALT on POD 1 **(B)**, AST on POD 1 **(C)**.](fphar-10-01442-g003){#f3}

Postoperative Inflammatory Response {#s3_4}
-----------------------------------

Serum IL-6 level on POD 1 (MD, −57.98; 95% CI, −73.04 to −42.91; *P* \< 0.00001) ([**Figure 4A**](#f4){ref-type="fig"}) and CRP level on POD 3 (MD, −4.83; 95% CI, −6.07 to −3.59; *P* \< 0.00001) ([**Figure 4B**](#f4){ref-type="fig"}) were significantly reduced in the steroid group comparing to the control group. Compared with the control group, the level of early postoperative IL-10 was significant higher in the steroid group (MD, 17.89; 95% CI, 3.89 to 31.89; *P* = 0.01) ([**Figure 4C**](#f4){ref-type="fig"}).

![The pooled results of comparison between the steroid group and the control group for postoperative inflammatory response and length of hospital stay illustrated by forest plots. The results were IL-6 on POD 1 **(A)**, CRP on POD 3 **(B)**, early postoperative IL-10 **(C)**, length of hospital stay **(D)**.](fphar-10-01442-g004){#f4}

Hospital Stay {#s3_5}
-------------

For length of hospital stay, there was no statistically significant difference between the steroid group and the control group (MD, −0.75; 95% CI, −3.03 to 1.53; *P* = 0.52) ([**Figure 4D**](#f4){ref-type="fig"}).

Quality of the Included Studies {#s3_6}
-------------------------------

The evaluation of the risk of bias for included studies is shown in [**Figure 5**](#f5){ref-type="fig"} according to the Cochrane Collaboration's Risk of Bias Tool. Due to a small number of included studies, the test power was insufficient and the symmetry was difficult to evaluate, funnel plot analysis was not carried out.

![Risk of bias summary. Dash sign: high risk of bias; plus sign: low risk of bias; question mark sign: unclear risk of bias.](fphar-10-01442-g005){#f5}

Subgroup Analysis {#s3_7}
-----------------

Subgroup analyses were conducted for overall complications ([**Figure 6**](#f6){ref-type="fig"}), TB on POD 1 ([**Figure 7**](#f7){ref-type="fig"}), and IL-6 on POD 1 ([**Figure 8**](#f8){ref-type="fig"}) based on region, method of vascular control, sample size, and drug regimen. The summary of subgroup analyses are presented in [**Table 4**](#T4){ref-type="table"}.

![Subgroup analysis of overall complications stratified by region **(A)**, method of vascular control **(B)**, sample size **(C)**, and drug regimen **(D)**.](fphar-10-01442-g006){#f6}

![Subgroup analysis of TB on POD 1 stratified by region **(A)**, method of vascular control **(B)**, sample size **(C)**, and drug regimen **(D)**.](fphar-10-01442-g007){#f7}

![Subgroup analysis of IL-6 on POD 1 stratified by region **(A)**, method of vascular control **(B)**, sample size **(C)**, and drug regimen **(D)**.](fphar-10-01442-g008){#f8}

###### 

Summary of the subgroup analysis.

  Outcome                 Subgroup                                     No. of studies   MD/OR (95% CI)              P value for overall effect   I^2^ value   P value for heterogeneity
  ----------------------- -------------------------------------------- ---------------- --------------------------- ---------------------------- ------------ ---------------------------
  Overall complications   Studies from Japan                           2                0.90 (0.52, 1.55)           0.70                         0            0.97
                          Studies from Italy                           3                0.41 (0.11, 1.50)           0.18                         63%          0.07
                          Studies from Germany                         1                0.58 (0.07, 4.56)           0.61                         ---          ---
                          Studies with continuous Pringle maneuver     2                0.59 (0.22, 1.63)           0.31                         0            0.63
                          Studies with intermittent Pringle maneuver   3                0.54 (0.13, 2.19)           0.39                         78%          0.010
                          Studies without Pringle maneuver             1                0.58 (0.07, 4.56)           0.61                         ---          ---
                          Studies with large sample (\>40)             3                0.43 (0.14, 1.31)           0.14                         76%          0.01
                          Studies with small sample (\<40)             3                0.98 (0.30, 3.15)           0.97                         0            0.78
                          Studies with dosage of 30 mg/kg              2                0.53 (0.20, 1.45)           0.22                         0            0.92
                          Studies with dosage of 500 mg                4                0.59 (0.19, 1.82)           0.36                         68%          0.03
  TB on POD 1             Studies from Japan                           2                −0.28 (−0.51, −0.05)        **0.02**                     30%          0.23
                          Studies from Italy                           3                −0.79 (−1.46, −0.13)        **0.02**                     81%          0.005
                          Studies from Germany                         1                −0.10 (−0.94, 0.74)         0.82                         ---          ---
                          Studies with continuous Pringle maneuver     2                −0.44 (−0.83, −0.05)        **0.03**                     0            0.54
                          Studies with intermittent Pringle maneuver   3                −0.72 (−1.36, −0.07)        **0.03**                     93%          *P* \< 0.00001
                          Studies without Pringle maneuver             1                −0.10 (−0.94, 0.74)         0.82                         ---          ---
                          Studies with large sample (\>40)             3                −0.63 (−1.50, 0.25)         0.16                         92%          *P* \< 0.00001
                          Studies with small sample (\<40)             3                −0.52 (−0.78, −0.26)        ***P* \< 0.0001**            0            0.56
                          Studies with dosage of 30 mg/kg              2                −0.15 (−0.75, 0.45)         0.63                         0            0.87
                          Studies with dosage of 500 mg                4                −0.66 (−1.15, −0.17)        **0.008**                    89%          *P* \< 0.00001
  IL-6 on POD 1           Studies from Japan                           2                −59.75 (−83.59, −35.91)     ***P* \< 0.00001**           67%          0.08
                          Studies from Italy                           2                −104.22 (−237.80, 29.36)    0.13                         82%          0.02
                          Studies from Germany                         1                −75.30 (−128.95, −21.65)    **0.006**                    ---          ---
                          Studies with continuous Pringle maneuver     2                −105.60 (−235.33, 24.13)    0.11                         81%          0.02
                          Studies with intermittent Pringle maneuver   2                −59.00 (−87.08, −30.93)     ***P* \< 0.0001**            71%          0.06
                          Studies without Pringle maneuver             1                −75.30 (−128.95, −21.65)    **0.006**                    ---          ---
                          Studies with large sample (\>40)             3                −72.45 (−111.67, −33.23)    **0.0003**                   77%          0.01
                          Studies with small sample (\<40)             2                −51.11 (−58.05, −44.17)     ***P* \< 0.00001**           0            0.37
                          Studies with dosage of 30 mg/kg              2                −118.46 (−223.81, −13.11)   **0.03**                     66%          0.09
                          Studies with dosage of 500 mg                3                −52.54 (−62.94, −42.14)     ***P* \< 0.00001**           43%          0.17

Bold text indicates statistical significance; RCT, randomized controlled trial; MD, mean difference; OR, odds ratio; CI, confidence interval.

Subgroup Analysis of Overall Complications {#s3_8}
------------------------------------------

No significant change was detected in the subgroup analysis of overall complications, the results were consistent with the aforementioned outcome. However, low heterogeneity of overall complications was found in studies from Japan (*I* ^2^ = 0), studies with continuous Pringle maneuver (*I* ^2^ = 0), studies with small sample (*I* ^2^ = 0), and studies with dosage of 30 mg/kg (*I* ^2^ = 0), indicating that region, method of vascular control, sample size, and drug regimen were potential sources of heterogeneity.

Subgroup Analysis of TB on POD 1 {#s3_9}
--------------------------------

The difference of TB on POD 1 was not significant between the steroid group and the control group in studies with large sample or studies with dosage of 30 mg/kg. Low heterogeneity of TB on POD 1 was detected in studies with continuous Pringle maneuver (*I* ^2^ = 0), studies with small sample (*I* ^2^ = 0), and studies with dosage of 30 mg/kg (*I* ^2^ = 0), implying that method of vascular control, sample size, and drug regimen were potential sources of heterogeneity.

Subgroup Analysis of IL-6 on POD 1 {#s3_10}
----------------------------------

The difference of IL-6 on POD 1 was not significant between the two groups in studies from Italy or studies with continuous Pringle maneuver. Low heterogeneity of IL-6 on POD 1 was observed in studies with small sample (*I* ^2^ = 0), suggesting that sample size was potential source of heterogeneity.

Sensitivity Analysis {#s3_11}
--------------------

Sensitivity analyses were also performed for overall complications, TB on POD 1, and IL-6 on POD 1, in which one study was removed at a time to assess the stability of the pooled results. Sensitivity analyses showed that pooled results did not change significantly with exclusion of the included studies in turn. The pooled results of overall complications, TB on POD 1, and IL-6 on POD 1 ranged from (OR, 0.46; 95% CI, 0.19--1.12; *I* ^2^ = 37%; *P* = 0.09), (MD, −0.64; 95% CI, −1.08 to −0.19; *I* ^2^ = 73%; *P* = 0.005), (MD, −71.11; 95% CI, −102.48 to −39.75; *I* ^2^ = 67%; *P* \< 0.00001) to (OR, 0.83; 95% CI, 0.52--1.32; *I* ^2^ = 0; *P* = 0.43), (MD, −0.34; 95% CI, −0.52 to −0.15; *I* ^2^ = 21%; *P* = 0.0004), (MD, −53.03; 95% CI, −62.65 to −43.41; *I* ^2^ = 30%; *P* \< 0.00001).

Discussion {#s4}
==========

In the present study, we performed a meta-analysis of preoperative administration of steroid in liver resection, demonstrating that steroid can promote the recovery of liver function and inhibit the inflammatory response without increasing postoperative complications after hepatectomy.

Serum TB is an important clinical parameter for postoperative liver dysfunction and also a critical prognosis relevant factor. The level of TB on POD 1 was significantly decreased associated with the use of steroid. The lower TB level in steroid group might be the result of a faster recovery of the liver. However, for the level of ALT and AST on POD 1, no statistical difference was detected between the steroid group and the control group according to the pooled results. This may be caused by different composition of patients in each included study. The study by [@B26] indicates that in patients with chronic liver diseases and AST and ALT levels on POD 1 were significantly lower in the steroid group than the control group. Nevertheless, in patients with normal liver, no statistical difference was found. Hence, the patients with chronic liver diseases may benefit more from preoperative administration of steroid and the steroid should be more often implemented in these patients.

As one of the most vital organs, the liver plays an important role in metabolic, secretory, and endocrine, which producing inflammatory factors, modifying coagulation balance, and regulating protein metabolism ([@B5]). Cytokines released from stimulated macrophages and monocytes after liver resection, this reaction is called the hepatic acute response. In the acute response, IL-6 acts as a critical modulator of the inflammation, not only influencing B-lymphocytes and T-lymphocytes, but inducing the production of acute-phase proteins in the liver, such as CRP, antiproteinases, and fibrinogen ([@B25]). Elevated blood cytokines can increase the risk of postoperative complications ([@B21]), therefore treatments to limit the cytokine response is needed. With the administration of steroid, IL-6, and CRP were significantly suppressed in the steroid group comparing to the control group. Previous research showed that the release of IL-6 is associated with the extent of liver resection, duration of operation, and volume of blood loss ([@B6]). And the two included studies ([@B1]; [@B8]) demonstrated that protective effects of preoperative steroid administration were more conspicuous in patients with larger resection volume and longer ischemic time. In liver resection, the release of IL-6 is augmented by the use of Pringle maneuver, owing to the IR injury. Both continuous and intermittent Pringle maneuver were used in the included studies. However, the subgroup analysis of IL-6 on POD 1 demonstrated that steroid can lead to a better outcome in studies with intermittent Pringle maneuver. IL-10 is a potent anti-inflammatory cytokine produced primarily by activated macrophages after liver surgery, it inhibits the release of pro-inflammatory cytokines and therefore tends to down-regulate the inflammatory reaction ([@B17]). In this meta-analysis, use of the steroid was relevant to a significant increase of serum IL-10 level in early postoperative period. Consequently, maintaining the balance of pro- and anti-inflammatory cytokines is a key factor to the recovery of patients undergoing liver surgery.

Prophylactic administration of steroid may potentially induce unnecessary side effects, such as postoperative infection, delayed wound healing, impaired liver regeneration. However, our pooled results indicated that preoperative use of steroid have no effect on the incidence of overall complications between the steroid group and the control group. In terms of specific complications, steroid also does not increase the incidence of infection complications, wound complications, liver failure, bile leakage, and pleural effusion. Besides, the subgroup analyses of overall complications suggested similar results. One ([@B1]) of the included studies reported that the infective complications were more frequent in the control group than the steroid group, yet other studies demonstrated no statistical difference was found between the two groups. This result was seemly paradoxical, however, Yamashita et al. ([@B39]) previously reported that preoperative use of steroid can decrease the serum level of immunosuppressive antigen and the positive rate of serum candida antigen, a marker of bacterial translocation. And similar findings were reported in esophagectomy ([@B35]). Takeda et al. ([@B36]) previously proposed the non regeneration type liver failure was mainly induced by severe IR injury after hepatectomy based on histological findings. And some literature reported that the overproduction of IL-6 during IR injury may inhibit liver regeneration ([@B38]). Steroid can suppress IL-6 production, therefore, preoperative administration of steroid may have a positive effect on liver failure after liver resection. Though this meta-analysis showed that no significant difference was detected in the incidence of liver failure between the two groups. Despite great technical advances, bile leakage after liver resection remains a main postoperative complication. A previous study reported that immunosuppression may repress cholangiocyte regeneration by inhibiting signal transducer and activator of transcription 3 activation in a rat liver transplantation model ([@B7]). So far, no research show any available evidence about the effect of steroids on cholangiocyte regeneration. The pooled result of our meta-analysis indicated that there was no significant difference in bile leakage between the two groups.

Long-term follow-up is required for these patients after liver resection, because there are some concerns about the risk of tumor recurrence may cause by the anti-inflammatory effect of steroid. Recently, [@B27] reported that prophylactic administration of steroid in patients undergoing transcatheter arterial chemoembolization can achieve a greater overall complete response rate than control group. This result indicated that a short-term administration of steroid did not significantly affect tumor treatment. But more research is needed to solve this issue.

Some limitations existed in this meta-analysis. First, most of the studies included in this meta-analysis were relatively small sample sizes and lack of long-term follow-up data. Large sample size RCTs with long-term follow-up are urgently needed in the future. Second, postoperative complications were vital parameters to evaluate the safety of preoperative steroid administration, but only four studies reported specific complications. Third, some date were extracted from graphs in original studies, because we failed to contact with corresponding author. This method may cause measurement bias.

In conclusion, preoperative administration of steroid in liver resection can promote the recovery of liver function and inhibit the inflammatory response without increasing postoperative complications. The steroid effect was associated with underlying liver disease and liver surgery itself (extent of liver resection and ischemic time), whether the steroid should be used routinely in all patients before liver resection remains unresolved. Further studies are required to explore this strategy.
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